LifeGene BioMarks

At present, women over 30 years old are recommended to schedule cervical cancer screening every three years. In most countries, the gold standard for cervical cancer detection includes Pap smear and HPV tests. Women with an abnormal Pap test and and HPV positive test are referred for a colposcopy-driven biopsy. While a majority of these tests come back negative, biopsies are regularly administered. The current process is often emotionally taxing for women and creates unnecessary health costs.

LifeGene’s precision methylation kits will revolutionize cervical cancer screening. We are developing a non-invasive, streamlined solution for cervical cancer screening and prevention that uses a panel of precision epigenetic markers to identify aggressive cervical disease before a colposcopy-driven biopsy is prescribed. The result? Better prevention, at a lower cost.